RDEA: Summary for Ardea Biosciences, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 6:29am EST - Canadian Markets open in 3 hours and 1 minute.

To create a watchlist or portfolio of shares, Sign-in or Register

Ardea Biosciences, Inc. (RDEA)

On Feb 9: 14.56 USD 0.00 (0.00%)

MORE ON RDEA

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Ardea Biosciences, Inc. (NGM:RDEA) Delayed quote data

Last Trade:	14.56 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	14.56
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	20.00

Day's Range:	N/A - N/A
52wk Range:	8.78 - 21.35
Volume:	0
Avg Vol (3m):	104,554
Market Cap:	268.12M
P/E (ttm):	N/A
EPS (ttm):	-1.74
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add RDEA to Portfolio

Download Data

HEADLINES

•	Ardea Biosciences names Felix Baker to board
	AP (Tue 1:08pm)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Tue 8:45am)

•	Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
	PRNewswire (Tue 8:30am)

•	Ardea Biosciences to Present at the 12th Annual BIO CEO and Investor Conference
	PRNewswire (Fri, Feb 5)

•	Coverage initiated on Ardea Biosciences by Soleil
	Briefing.com (Thu, Jan 28)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
	EDGAR Online (Mon, Jan 11)

•	Ardea Biosciences rises on gout drug study results
	AP (Thu, Jan 7)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Regulation FD Disclosure
	EDGAR Online (Thu, Jan 7)

•	Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat
	PRNewswire (Thu, Jan 7)

•	ARDEA BIOSCIENCES, INC./DE Files SEC form 8-K, Entry into a Material Definitive Agreement
	EDGAR Online (Tue, Dec 22)

More Headlines for RDEA...

ANALYST

EPS Est (next year) (Dec-07) :	-2.46
EPS Est (in 2 years) (Dec-08) :	-3.22
Avg Rec (current)*:	1.3
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Ardea Biosciences, Inc. engages in the research and development of pharmaceutical products for the treatment of HIV, cancer, and inflammatory diseases in the United States.

Full Company Profile

Add to Portfolio

Email to a Friend

•